First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers

• Main Authors: Fei Tang (Author), Rebecca Kunder (Author), Tom Chu (Author), Avis Hains (Author), Allen Nguyen (Author), Jacqueline M. McBride (Author), Yu Zhong (Author), Sara Santagostino (Author), Maria Wilson (Author), Abigail Trenchak (Author), Liuxi Chen (Author), Justin Ly (Author), Anita Moein (Author), Nicholas Lewin‐Koh (Author), Vibha Raghavan (Author), Uyi Osaghae (Author), Chris Wynne (Author), Ryan Owen (Author), David Place (Author)
• Format: Book
• Published: Wiley, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Inappropriate and chronic activation of the cytosolic NOD‐, LRR‐, and pyrin domain‐containing 3 (NLRP3) inflammasome, a key component of innate immunity, likely underlies several inflammatory diseases, including coronary artery disease. This first‐in‐human phase I trial evaluated safety, ph...